Want to see CBLL full AI Analyst Report?
CBLL Stock Chart & Stats
$18.36
-$0.15(-0.64%)
At close: 4:00 PM EST
$18.36
-$0.15(-0.64%)
Day’s Range― - ―
52-Week Range$10.85 - $24.33
Previous CloseN/A
Volume46.56K
Average Volume (3M)265.67K
Market Cap
$736.09M
Enterprise Value$632.51M
Total Cash (Recent Filing)$141.18M
Total Debt (Recent Filing)$22.12M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 11, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding37,942,700
10 Day Avg. Volume244,220
30 Day Avg. Volume265,666
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.16
Price to Sales (P/S)9.00
P/FCF Ratio-19.28
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue6.65
Enterprise Value/Gross Profit7.59
Enterprise Value/Ebitda-11.04
Forecast
1Y Price Target
$28.50Price Target Upside55.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$113.99M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And Hospital PenetrationSustained top-line growth and unusually strong account adds (680 hospitals, +33 net) indicate durable commercial adoption of Ceribell’s point-of-care EEG platform. Continued expansion across hospitals and rising headband utilization support predictable recurring product and subscription revenue over the medium term.
Very High, Consistent Gross MarginsConsistently high gross margins (mid-to-high 80s) reflect favorable unit economics of the headband plus software model. High margins create durable operating leverage as revenue scales, enabling incremental revenue to more meaningfully offset fixed R&D and S&M spend over time.
Solid Liquidity And Manageable LeverageA cash balance north of $140M combined with modest debt provides near-term runway to fund commercialization, regulatory milestones, and manufacturing transitions. Manageable leverage reduces refinancing risk and gives management flexibility to invest in growth while pursuing break-even milestones.
Bears Say
Persistent Negative Operating Cash FlowOperating cash flow has been consistently negative and roughly tracks net losses, producing sustained cash burn. This structural cash outflow increases dependence on external financing, which can dilute shareholders and constrain strategic flexibility until operating cash generation improves.
Rising Operating Expenses And Litigation DragMaterial YoY OpEx increases driven by S&M and R&D, plus elevated IP litigation costs, raise the structural burn rate and delay operating leverage. Persistent elevated SG&A and legal spend can slow progress to profitability even if revenue momentum continues, prolonging funding needs.
Deeply Negative Net Margins And Ongoing LossesLarge negative net margins reflect operating losses that remain far from break-even despite revenue gains. Continued sizeable losses erode equity, increase dilution risk, and mean profitability depends on sustained revenue growth plus disciplined expense control—outcomes that are not yet demonstrated.
Ceribell, Inc. News
CBLL FAQ
What was Ceribell, Inc.’s price range in the past 12 months?
Ceribell, Inc. lowest stock price was $10.85 and its highest was $24.33 in the past 12 months.
What is Ceribell, Inc.’s market cap?
Ceribell, Inc.’s market cap is $736.09M.
When is Ceribell, Inc.’s upcoming earnings report date?
Ceribell, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 32 days.
How were Ceribell, Inc.’s earnings last quarter?
Ceribell, Inc. released its earnings results on May 11, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.129.
Is Ceribell, Inc. overvalued?
According to Wall Street analysts Ceribell, Inc.’s price is currently Undervalued.
Does Ceribell, Inc. pay dividends?
Ceribell, Inc. does not currently pay dividends.
What is Ceribell, Inc.’s EPS estimate?
Ceribell, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Ceribell, Inc. have?
Ceribell, Inc. has 37,942,700 shares outstanding.
What happened to Ceribell, Inc.’s price movement after its last earnings report?
Ceribell, Inc. reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went down -16.5%.
Which hedge fund is a major shareholder of Ceribell, Inc.?
Currently, no hedge funds are holding shares in CBLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ceribell, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.50 (55.23% Upside)
$28.50 (55.23% Upside)
Blogger Sentiment
Bullish
CBLL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.74%
12-Months-Change
Fundamentals
Return on Equity
-38.19%
Trailing 12-Months
Asset Growth
-16.58%
Trailing 12-Months
Company Description
Ceribell, Inc.
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
CBLL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and robust top-line growth (29% YoY revenue, record account additions, high 87% gross margin), alongside several strategic milestones (neonate/pediatric launches, delirium pilot with FDA clearance, favorable NTAP proposal, LVO Breakthrough designation) and a healthy cash position. Offsetting these positives are elevated operating expenses (+36% YoY), significant near-term litigation costs ($5.6M in Q1), a wider net loss ($19.7M), and continued adjusted EBITDA losses. Given the combination of accelerating revenue/market expansion and manageable but notable near-term expense pressures, the tone is constructive with near-term investment-driven profitability headwinds.View all CBLL earnings summariesCBLL Stock 12 Month Forecast
Average Price Target
$28.50
▲(55.23% Upside)
Technical Analysis
Ownership Overview
26.42% Insiders
25.95% Mutual Funds
0.09% Other Institutional Investors
39.81% Public Companies and
Individual Investors